Prostate Cancer
Calcitriol might enhance effect of taxotere
Published in Cancer Weekly, October 11th, 2005
According to a study from the United States, "ASCENT, the Androgen-Independent Prostate Cancer (AIPC) Study of Calcitriol Enhancing Taxotere, is a double-blind, placebo-controlled randomized clinical trial designed to determine if DN-101, a high-dose oral formulation of calcitriol designed for cancer therapy, significantly increases the proportion of patients who have >50% reduction in serum prostate-specific antigen (PSA) levels in response to docetaxel."
"The secondary goals of ASCENT are to evaluate the effect of DN-101 combined with docetaxel on PSA progression-free survival,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-10-11)
More Articles from Cancer Weekly
- Breast Cancer
Molecular tumor subtype influences preoperative chemotherapy efficacy - Cancer Therapy
Cone-beam-CT guided radiation therapy used as model for on-line application - Cancer Therapy
Intensity-modulated radiation therapy used in head and neck cancers - Lung Cancer
Asian ethnicity and adenocarcinoma histology predicted response to gefitinib - Prostate Cancer
Active Stat5 predicts early recurrence - Acute Lymphoblastic Leukemia
Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
